San Francisco startup Grand Rounds is offering second opinions to cut down on unnecessary or inappropriate surgeries. It just announced a $55 million VC haul, to take its total to $106 million.
As Lundbeck cuts staff and reshuffles R&D, one of its drug candidates has come out a winner.
Google has faced some stumbling blocks with Google Glass since launching the product in 2013, deciding earlier this year to stop selling the device to consumers in light of waning sales. But the company is set to meet increased demand for the product among devicemakers as a new version of Glass hits the market.
Scientists at Nottingham Trent University, Nottingham University Hospitals NHS Trust and the University of Nottingham have identified a possible target for triple negative breast cancers, offering vaccine makers a potential path forward against the cancer and patients hope where other treatments have failed.
While San Diego-based Pfenex's primary focus isn't on vaccines, the company gained a big backer in the space Monday with the announcement that the U.S. government has agreed to work with the biotech on its anthrax vaccine candidate for bioterror protection.
Lundbeck has initiated a rejig of its pipeline, taking an ax to undisclosed early-stage assets in order to funnel cash into what it sees as its most promising candidates. The schizophrenia drug Lu AF35700 is among the beneficiaries of the reshuffle, with Lundbeck using its reorganized balance sheet to advance the therapy through development unpartnered.
GlaxoSmithKline is laying off nearly 1,000 employees in North Carolina in an effort to trim its R&D costs, cutting deep into the biotech ecosystem in Research Triangle Park. But a handful of ex-GSK researchers have swiftly moved on, starting up a biotech to develop peptide therapies of their own.
Six months after Celsus Therapeutics' stock price collapsed on the mid-stage failure of its lead therapy, Geneva-based Volution Immuno Pharmaceuticals has stepped in with a reverse merger deal, lining up $75 million in fresh financing from some A-list investors and flipping the company into the public market with a new name and ticker symbol on Nasdaq.
Intarcia Therapeutics' matchstick-sized device for diabetes beat out Merck's blockbuster drug Januvia in a Phase III trial, burnishing its case for FDA approval next year.
Genetic data has already proven its clinical benefits, but still has a ways to go when it comes to consumerization, as evidenced by the demise of 23andMe's saliva-based Personal Genome Test at the hands of the FDA.